Abstract
Bleomycin is a commonly used chemotherapeutic agent for lymphomas, germ cell tumors, and malignant pleural effusions. Although the pulmonary toxicity of bleomycin is well reported; the cutaneous side effects are relatively uncommon, ranging from generalized hyperpigmentation, sclerodermoid changes, erythema multiforme, and gangrene to flagellate dermatosis. Here, we report a characteristic but relatively rare side effect of flagellate dermatitis, which developed secondary to bleomycin in a 28-year-old gentleman suffering from Hodgkin's lymphoma after two cycles of treatment with adriamycin, bleomycin, vinblastine, dacarbazine regimen.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
